
Please try another search
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Name | Age | Since | Title |
---|---|---|---|
Robert A. Bradway | 58 | 2007 | Chairman, CEO & President |
Tyler E. Jacks | 62 | 2012 | Independent Director |
David Baltimore | 85 | 1999 | Co-Chair of Scientific Advisory Board |
Charles M. Holley | 66 | 2017 | Independent Director |
Charles Elliott Sigal | 72 | - | Co-Chair of the Scientific Advisory Board |
Ellen J. Kullman | 68 | 2016 | Independent Director |
Robert A. Eckert | 70 | 2012 | Lead Independent Director |
Greg C. Garland | 67 | 2013 | Independent Director |
David J. Anderson | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Ruslan Medzhitov | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Peter Libby | 77 | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Daniel Joshua Drucker | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Frank P. McCormick | 74 | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Mary E. Klotman | - | 2024 | Director |
Jonathan S. Weissman | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
E. Dale Abel | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Jeffery D. Molkentin | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Ronald M. Evans | 75 | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Robert Tjian | 75 | - | Member of Scientific Advisory Board Member of Research Trends & Emerging Technologies |
Fabrice Andre | - | - | Member of Scientific Advisory Board of Oncology |
R. Sanders Williams | 75 | 2014 | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Amy E. Miles | 57 | 2020 | Independent Director |
Alexander Rudensky | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Diane J. Mathis | - | - | Member of Scientific Advisory Board of Inflammation |
Alexander Marson | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Arlene Sharpe | - | 2022 | Member of Scientific Advisory Board of Inflammation |
S. Omar Ishrak | 68 | 2021 | Independent Director |
S. Gail Eckhardt | - | 2022 | Member of Scientific Advisory Board of Oncology |
Daniel P. Kelly | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Robert S. Negrin | - | - | Member of Scientific Advisory Board of Oncology |
Antoni Ribas | 57 | - | Member of Scientific Advisory Board of Oncology |
Dean Sheppard | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Benoit Van den Eynde | - | - | Member of Scientific Advisory Board of Oncology |
Richard O. Hynes | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Brian J. Druker | 69 | 2018 | Independent Director |
Wanda M. Austin | 70 | 2017 | Independent Director |
John Kuriyan | - | - | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Lillian L. Siu | - | 2022 | Member of Scientific Advisory Board of Oncology |
Emma Guttman-Yassky | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Meilan Han | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Maria T. Abreu | - | 2022 | Member of Scientific Advisory Board of Inflammation |
Siwen Hu-Lieskovan | - | - | Member of Scientific Advisory Board of Oncology |
Dirk Jäger | - | - | Member of Scientific Advisory Board of Oncology |
Thomas Quertermous | 72 | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Michael V. Drake | 73 | 2022 | Independent Director |
George Georgiou | 65 | 2023 | Member of Scientific Advisory Board of Research Trends & Emerging Technologies |
Andrew Mark Pardoll | - | - | Member of Scientific Advisory Board of Oncology |
David Alan Kass | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Marlene Rabinovitch | - | - | Member of Scientific Advisory Board of Cardiovascular & Metabolic |
Randy J. Seeley | - | 2025 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review